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Summary
Background: Immunosuppressive agents are being investigated for the treatment of 
chronic	kidney	disease	(CKD)	but	may	increase	risk	of	infection.	This	was	a	retrospec-
tive	 observational	 study	 intended	 to	 evaluate	 the	 risk	 of	 hospitalized	 infection	 in	
patients	with	CKD,	 by	 estimated	 glomerular	 filtration	 rate	 (eGFR)	 and	proteinuria	
status,	aiming	to	identify	the	most	appropriate	disease	stage	for	immunosuppressive	
intervention.
Methods:	Routine	UK	primary-	care	and	linked	secondary-	care	data	were	extracted	
from	 the	Clinical	Practice	Research	Datalink.	Patients	with	a	 record	of	CKD	were	
identified	and	grouped	into	type	2,	type	1	and	nondiabetes	cohorts.	Time-	dependent,	
Cox	proportional	hazard	models	were	used	to	determine	the	likelihood	of	hospital-
ized	infection.
Results:	We	identified	97	839	patients	with	a	record	of	CKD,	of	these	11	719	(12%)	
had type 2 diabetes.	In	these	latter	patients,	the	adjusted	hazard	ratios	(aHR)	were	
1.00	 (95%	CI:	0.80-	1.25),	1.00,	1.03	 (95%	CI:	0.92-	1.15),	1.36	 (95%	CI:	0.20-	1.54),	
1.82	(95%	CI:	1.54-	2.15)	and	2.41	(95%	CI:	1.60-	3.63)	at	eGFR	stages	G1,	G2	(refer-
ence),	G3a,	G3b,	G4	and	G5,	respectively;	and	1.00,	1.45	(95%	CI:	1.29-	1.63)	and	1.91	
(95%	CI:	1.67-	2.20)	at	proteinuria	stages	A1	(reference),	A2	and	A3,	respectively.	All	
aHRs	(except	G1	and	G3a)	were	significant,	with	similar	patterns	observed	within	the	
non-	DM	and	overall	cohorts.
Conclusions:	eGFR	and	degree	of	albuminuria	were	independent	markers	of	hospi-
talized	 infection	 in	both	patients	with	and	without	diabetes.	The	same	patterns	of	
hazard	ratios	of	eGFR	and	proteinuria	were	seen	in	CKD	patients	regardless	of	diabe-
tes	status,	with	the	risk	of	each	outcome	increasing	with	a	decreasing	eGFR	and	in-
creasing	proteinuria.	Infection	risk	increased	significantly	from	eGFR	stage	G3b	and	
proteinuria	stage	A2	in	type	2	diabetes.	Treating	type	2	DM	patients	with	CKD	at	
eGFR	stages	G1-	G3a	with	immunosuppressive	therapy	may	therefore	provide	a	fa-
vourable	 risk-	benefit	 ratio	 (G1-	G3a	 in	 type	2	diabetes;	G1-	G2	 in	 nondiabetes	 and	
overall	cohorts)	although	the	degree	of	proteinuria	needs	to	be	considered.
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1  | INTRODUC TION
Diabetic	nephropathy	is	the	leading	cause	of	chronic	kidney	disease	
(CKD)	in	all	developed	and	most	developing	countries.1 Gradual de-
struction	of	the	kidney	glomeruli	in	patients	with	type	1	and	type	2	
diabetes	causes	declining	renal	function,	manifesting	as	decreased	
glomerular	filtration	rate	(GFR),	proteinuria2 and hypertension.3
At	present,	relevant	renal	treatments	focus	on	inhibiting	the	pro-
gression of nephropathy by maintaining good metabolic and hemo-
dynamic control. Glycemic control is an important factor in reducing 
the	 microvascular	 complications	 that	 lead	 to	 nephropathy:	 the	 UK	
Prospective	 Diabetes	 Study	 (UKPDS)	 showed	 that	 diabetic	 patients	
receiving	 glucose-	lowering	 treatment	 who	 achieved	 good	 glycemic	
control	were	less	likely	to	progress	to	end-	stage	renal	disease	(ESRD).4 
Antihypertensives	 such	 as	 angiotensin-	converting-	enzyme	 (ACE)	
inhibitors	 and	 angiotensin	 receptor	 blockers	 (ARBs)	 also	 play	 a	 role	
in	 slowing	 the	progression	of	 kidney	disease	by	 inhibiting	 the	 renin-	
angiotensin-	aldosterone	system.	The	ADVANCE	trial	reported	reduced	
onset of microalbuminuria and no progression to nephropathy from 
existing	microalbuminuria	in	patients	with	type	2	diabetes	treated	with	
the	ACE	inhibitor	perindopril	combined	with	indapamide,5 while a trial 
conducted	by	Brenner	et	al6	found	that	the	risk	of	ESRD	was	reduced	
by	28%	in	patients	with	type	2	diabetes	receiving	the	ARB	losartan.
However,	there	is	emerging	evidence	that	inflammatory	processes	
and immune activation play an important role in the progression of 
diabetic nephropathy.7,8	 Therefore,	 new	 therapeutic	 strategies	 for	
slowing	or	reversing	the	decline	in	kidney	function	and	progression	to	
ESRD	have	been	proposed	that	would	target	the	immune	system	itself	
in	order	 to	minimize	 inflammation.9-12	Such	an	approach	may,	how-
ever,	bring	with	it	an	increased	risk	of	infection,	which	is	a	recognized	
complication	 of	 kidney	 disease13,14	 and,	 separately,	 of	 diabetes.15 
Therefore,	a	careful	evaluation	of	the	risk-	benefit	profile	of	using	such	
therapies in patients with diabetic nephropathy is warranted.
Currently,	there	are	limited	data	available	describing	the	true	in-
cidence of infections in the diabetic nephropathy population specifi-
cally,	and	how	this	varies	by	CKD	stage	and	the	degree	of	proteinuria.	
McDonald et al16 demonstrated an association between decreased 
renal	 function	and	community-	acquired	 lower	 respiratory	 tract	 in-
fection,	pneumonia	and	sepsis	 in	patients	with	diabetes	and	CKD,	
identifying	proteinuria	as	an	independent	risk	marker.	However,	this	
study	was	limited	in	that	it	excluded	subjects	younger	than	65	years.
Here,	our	objectives	were	to	characterize	the	risk	of	severe	in-
fection	 in	adult	patients	with	CKD	 in	 type	2	diabetes,	with	similar	
data for those with nondiabetes and type 1 diabetes for complete-
ness,	 in	order	 to	determine	how	severe	 infections	varied	by	eGFR	
stage	and	severity	of	proteinuria.	Furthermore,	we	aimed	to	identify	
where	infection	risk	was	lowest,	in	order	to	identify	the	most	appro-
priate stage in which to intervene with immunosuppressants.
2  | METHODS
2.1 | Study design and data sources
Data	 for	 this	 retrospective	 cohort	 study	 were	 from	 the	 UK	 
Clinical	 Practice	 Research	 Datalink	 (CPRD),17 a governmental 
research	service	that	provides	anonymized	electronic	health	re-
cords	gathered	directly	 from	primary-	care	practices	 throughout	
the	UK.
The	CPRD	collects	data	from	nearly	700	primary-	care	practices,	
representing	 7%	 of	 practices	 in	 the	 UK	 National	 Health	 Service	
(NHS).	Over	98%	of	 the	UK	population	 is	 registered	with	 an	NHS	
primary-	care	practice;	care	is	free	of	charge.	The	primary-	care	prac-
titioner	(general	practitioner	[GP])	acts	as	a	gateway	to	care	and	is	
the	first	point	of	contact	for	nonemergency	health	concerns,	refer-
ring the patient to secondary care as necessary.
At	July	2015,	CPRD	contained	data	from	more	than	13	million	
research-	quality	 patients.	 Recorded	 data	 include	 demographics,	
clinical	 symptoms	 and	 diagnoses,	 tests	 ordered	 in	 primary	 care,	
assessments	(such	as	blood	pressure,	body	mass	index),	prescrip-
tions	 and	 referrals	 to	 secondary	 care.	 For	 approximately	50%	of	
patients	 in	 CPRD,	 linked	 secondary-	care	 data	 are	 available	 from	
the	Hospital	Episode	Statistics	(HES),18 including inpatient diagno-
ses	and	procedures.	These	linked	patients	have	been	found	to	be	
representative	of	the	entire	CPRD	data	set,	which	is,	in	turn,	con-
sidered	representative	of	the	UK	population	as	a	whole	in	terms	of	
age	and	sex.17,19	Diagnoses	in	CPRD	primary-	care	and	HES	data	are	
encoded	using	 the	Read	 (Clinical	Terms)	and	 ICD-	10	dictionaries,	
respectively.
Approval	for	this	study	was	granted	by	the	CPRD	Independent	
Scientific	Advisory	Committee,	reference	number	017_191R.
2.2 | Study population
Patients	 were	 included	 if	 their	 patient-	level	 information	 and	
practice-	recording	systems	were	classed	as	being	of	acceptable	re-
search	quality	by	CPRD.	Patients	were	also	 required	 to	be	eligible	
to	have	 their	 records	 linked	 to	 the	HES	data	 set.	The	observation	
period	began	in	1997	and	ended	in	2014.	The	following	patient	se-
lection criteria were also applied:
•	 At	least	one	recorded	diagnosis	of	CKD
•	 Two	or	more	positive	(<90	mL/min/1.73	m2)	estimated	glomerular	
filtration	rates	(eGFR)	91-730	days	apart
•	 Registration	 at	 the	practice	 for	365	days	or	more	 at	 index	date	
(defined	as	the	earlier	of	the	patient’s	first	positive	eGFR	or	pro-
teinuria	test).	Positive	proteinuria	tests	that	were	on	the	same	day	
or had the same consultation identifier as a record of urinary tract 
infection	were	excluded.
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•	 Aged	40	years	 or	 older	 at	 index	date	 (25	years	 or	 older	 for	 pa-
tients	with	type	1	diabetes)
•	 No	prior	dialysis,	kidney	transplant,	or	cancer	at	index	date.
Patients	were	grouped	 in	 the	 following	cohorts:	 type	1	diabetes	
(T1DM),	 type	2	diabetes	 (T2DM)	or	no	diabetes	 (non-	DM)	based	on	
their	history	prior	to	index	date.
The selection criteria were modelled from a previous study con-
ducted	by	Schneider	et	al.20
Members	of	the	type	1	diabetes	(T1DM)	cohort	were	further	re-
quired	to	be	aged	25	years	or	older	at	index	date	and	to	have	at	least	
one	prescription	for	insulin	with	no	other	glucose-	lowering	agent,	no	
record	of	type	2	diabetes,	a	diabetes	presentation	date	on	or	before	
their	index	date	and	at	least	one	of	the	following:
•	 At	least	one	diagnosis	of	type	1	diabetes	using	a	diagnostic	code	
other	than	a	Read	code	for	“insulin-dependent	diabetes	mellitus”	
(a term that may be misapplied to patients with type 2 diabetes 
receiving	insulin	therapy)
•	 At	 least	 one	diagnosis	 of	 type	1	diabetes	 and	 aged	30	years	or	
younger at diabetes presentation (earlier of first insulin or first 
diagnosis)
Members	 of	 the	 type	 2	 diabetes	 (T2DM)	 cohort	 were	 required	
to	be	aged	40	years	or	older	at	 index	date	and	 to	have	a	diagnostic	
record	 of	 T2DM	or	 at	 least	 one	 prescription	 for	 a	 glucose-	lowering	
therapy	other	than	insulin,	no	record	of	secondary	diabetes	and	a	dia-
betes	presentation	on	or	before	their	index	date.	Patients	identified	by	
metformin	prescription	alone	were	excluded	if	they	had	a	diagnosis	of	
polycystic ovarian syndrome.
•	 At	least	one	diagnosis	of	type	1	diabetes,	aged	31-39	at	diabe-
tes	 presentation	 and	 a	 body	mass	 index	 (BMI)	 at	 presentation	
≤25	kg/m2.
Members	of	the	nondiabetes	(non-	DM)	cohort	were	required	to	
be	aged	40	years	or	older	at	index	date,	to	have	no	record	of	diabe-
tes	or	glucose-	lowering	 therapy	 in	 the	data	 source	and	 to	have	no	
more	 than	one	 record	of	glycosylated	haemoglobin	 (HbA1c)	≥6.5%	
(47.5	mmol/mol).
For	all	cohort	members,	the	end	of	data	follow-	up	was	calculated	as	
the	earliest	of:	the	patient’s	death	or	transfer-	out	date,	their	practice’s	
last	data-	collection	date,	the	patient’s	individual	HES	linkage	date	and	
the	end	of	the	linkage	scheme	(31	March	2014);	censoring	occurred	at	
first	dialysis,	kidney	transplant,	cancer	or	death	for	those	who	under-
went renal replacement therapy or died during the study period.
2.3 | Study end- points
For	all	cohorts,	the	study	end-	points	were:
• Event rates for all admissions to hospital with a primary diagnosis 
of infection
•	 Time	to	first	admission	for	infection,	stratified	by	eGFR	and	pro-
teinuria category
•	 Adjusted	 risk	 of	 first	 admission	 for	 infection	 by	 eGFR	 category	
and proteinuria level
Glomerular filtration rate values were estimated from serum 
creatinine	 test	 results	 by	 means	 of	 the	 CKD	 Epidemiology	
Collaboration	 (CKD-	EPI)	 equation,21 incorporating its adjustment 
for	 black	 ethnicity	 where	 this	 could	 be	 identified	 from	 CPRD	 or	
HES	data.
Tests for microalbuminuria and proteinuria (collectively termed 
proteinuria	hereafter)	are	recorded	in	the	CPRD	primary-	care	data	
in	five	different	test	“entities,”	3	of	which:	albumin-	creatinine	ratio,	
urine	microalbumin	and	urine	biochemistry	record	both	quantitative	
and	 qualitative	 results,	 while	 another	 two:	 urinalysis—protein	 and	
urine	dipstick	for	protein	contain	qualitative	results	only.	Test	data	
are	accompanied	by	Read	codes,	which	may	provide	more	informa-
tion	about	the	nature	of	the	test	or	of	its	result,	and	data	qualifiers	
(such	as	“normal,”	“negative,”	“+++”).
To address the challenge of identifying specific measures 
of proteinuria with appropriate units of measurement from the 
three	 quantitative	 entities,	we	 extended	 the	 approach	 of	 Liang	
et al22	 by	 classifying	 each	 test	 entity,	 unit	 of	measurement	 and	
accompanying	 Read	 code	 as	 specific,	 nonspecific,	 or	 conflict-
ing	 with	 	respect	 to	 each	 of	 these	 measures	 in	 turn:	 albumin-	
creatinine	ratio,	protein-	creatinine	ratio,	albumin	excretion	rate,	
protein	 excretion	 rate,	 spot	 albumin	 and	 spot	 protein.	 Records	
were selected if at least one dimension was specific for a mea-
sure,	with	no	conflicting	dimension.	Exceptions	to	this	rule	were:	
(a)	where	 the	Read	code	dimension	was	conflicting	but	 the	unit	
was	specific;	and	(b)	for	spot	albumin,	where	the	entity	was	con-
flicting	 (albumin-	creatinine	 ratio)	 but	 the	 unit	 of	 measurement	
was specific.
Qualitative	results	were	identified	from	the	qualitative	test	en-
tities	 and	 also	 from	quantitative	 records	 that	 did	not	meet	 any	of	
the	rules	listed	above	or	had	no	numeric	result	entered.	In	addition,	
clinical	records	from	CPRD	and	HES	were	included	as	qualitative	re-
sults	if	their	respective	Read	or	ICD-	10	codes	indicated	negative	or	
positive proteinuria.
Eight	categories	of	 infection	plus	all-	cause	 infection	were	con-
sidered,	as	selected	and	defined	by	Dalrymple	et	al14:	genitourinary,	
gastrointestinal,	 pulmonary,	 skin	 and	 soft	 tissue,	 sepsis,	 bone	 and	
joint,	endocarditis,	and	bacteremia.	Hospitalizations	for	each	infec-
tion	category	were	identified	from	the	linked	HES	data	by	appropri-
ate	ICD-	10	code,	where	that	infection	was	listed	as	the	main	reason	
(primary	diagnosis)	for	the	admission.
The	 eGFR	 and	 proteinuria	 data	 were	 derived	 from	 CPRD	 and	
HES	 records.	 In	 accordance	 with	 the	 Kidney	 Disease:	 Improving	
Global	Outcomes	(KDIGO)	clinical	practice	guidelines,23 the sever-
ity	of	CKD	was	graded	into	six	categories,	from	G1:	normal	or	high	
to	G5:	 kidney	 failure,	 based	 on	 the	 patient’s	 eGFR	measurements	
(Table	S1).	Classification	of	proteinuria	 severity	was	also	based	on	
a	KDIGO	classification,	from	A1:	normal	to	mildly	increased	to	A3:	
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severely	 increased,	with	a	 fourth	category,	A23,	added	 to	encom-
pass	qualitative	results	from	which	the	extent	of	abnormality	could	
not	be	determined	(Table	S2).20
Patients’	baseline	values	for	BMI,	weight,	height,	systolic	and	
diastolic	 blood	 pressure,	 creatinine	 and—for	 the	 diabetes	 co-
horts—HbA1c	 were	 identified	 from	 the	 nearest	 record	 to	 index	
date,	provided	this	was	no	more	than	365	days	before	or	30	days	
after	 index	 date	 and	 searching	 in	 the	 following	 order:	 −30	days,	
+30	days,	 −365	days.	 Baseline	 smoking	 and	 alcohol	 status	 were	
identified	from	the	nearest	record	prior	to	index	date;	 if	no	such	
status	was	recorded,	the	nearest	status	following	index	date	was	
used.
2.4 | Statistical methods
Baseline	characteristics	for	each	of	the	three	cohorts:	T2DM,	non-
	DM	and	T1DM	were	summarized.	Event	rates	for	all	admissions	to	
hospital with a primary diagnosis of infection were calculated per 
1000	patient	years’	(pkpy)	follow-	up.
For	each	 cohort,	Kaplan-	Meier	 curves	 for	 time	 to	 first	 hospi-
talization	for	infection	of	any	type	were	stratified	by	the	patient’s	
baseline	eGFR	and	proteinuria	category	at	or	nearest	to	infection	
admission.	Cox	proportional	hazard	models	were	used	to	estimate	
adjusted	hazard	ratios	 (aHR)	for	time	to	first	admission,	adjusting	
for	 eGFR	 category	 (reference	 G2,	 “mildly	 decreased”)	 and	 pro-
teinuria	level	(reference	A1,	“normal	to	mildly	increased”)	 in	quar-
terly	 updated	 time-	dependent	 models.	 Where	 appropriate,	 the	
models	were	 adjusted	 for	 age,	 gender,	 baseline	 body	mass	 index	
(BMI),	baseline	blood	pressure,	glycosylated	haemoglobin	(HbA1c),	
smoking	 status,	diabetes	 cohort,	 index	year	 and	prior	 comorbidi-
ties	(coronary	heart	disease	[CHD],	congestive	heart	failure	[CHF],	
hypertension	 cerebrovascular	 disease,	 dementia,	 other	 neurolog-
ical	 disorders,	 chronic	 obstructive	 pulmonary	 disease	 [COPD],	
chronic	 liver	disease	and	any	antihypertensives	 [ACE/ARB]	 in	the	
year	prior).	The	eGFR	level	G2	was	chosen	as	the	referent	because	
there	were	 small	 numbers	of	 patients	with	 an	eGFR	of	G1	 (“nor-
mal	or	high”)	at	index	date.	These	analyses	were	carried	out	using	
the	R	statistical	computing	environment,24 using the Therneau and 
Patricia	survival	package.25
3  | RESULTS
3.1 | Baseline characteristics
A	 total	 of	 97	839	patients	with	CKD	 fulfilled	 the	 selection	 crite-
ria,	 comprising	85	934	patients	 in	 the	 non-	DM	cohort,	 11	719	 in	
the	T2DM	cohort	and	186	 in	 the	T1DM	cohort.	Baseline	charac-
teristics for the three cohorts are detailed in Table 1. Mean age 
was	highest	in	the	non-	DM	cohort	(69.7	years,	SD	=	11.2),	followed	
by	the	T2DM	cohort	(67.0	years,	SD	=	10.2)	and	the	T1DM	cohort	
(47.9	years,	SD	=	13.7,	P	<	0.001).	There	were	slightly	more	males	
than	females	 in	the	T2DM	and	T1DM	cohorts:	53.5%	and	57.0%,	
respectively;	 the	 non-	DM	 cohort	 had	 more	 females:	 59.3%.	 As	
expected,	the	duration	of	diabetes	was	higher	in	the	T1DM	cohort	
than	in	the	T2DM	cohort:	20.64	years	vs	3.23	years,	respectively	
(P	<	0.001).
Of	the	97	839	study	patients,	99.1%	were	identified	by	(and	had	
their	index	date	set	by)	their	first	positive	eGFR	test.	Most	patients	
identified	by	eGFR	had	a	baseline	value	of	G2	 (50.0%	 in	non-	DM,	
60.1%	in	T2DM	and	54.3%	in	T1DM,	P	<	0.001).
3.2 | Crude hospitalization rates for infection
Rates of hospital admission for infection were higher in the T2DM 
cohort,	 at	 33.3	 admissions	 per	 1000	 patient	 years	 (pkpy),	 than	
in	 the	 non-	DM	 cohort	 (24.9	 admissions	 pkpy)	 and	 T1DM	 cohort	
(24.0	 pkpy,	 P	<	0.001,	 Table	2).	 Examining	 admissions	 by	 infec-
tion	 type,	 hospitalization	 rates	 in	 the	 T2DM	 cohort	 were	 higher	
than	 in	 the	 non-	DM	 cohort	 for	 genitourinary	 infection	 (10.5	 vs	
7.3	pkpy,	P	<	0.001,	respectively),	pulmonary	 infection	(7.8	vs	6.6	
pkpy,	 P	<	0.001,),	 skin	 and	 soft	 tissue	 infection	 (5.9	 vs	 2.9	 pkpy,	
P	<	0.001,),	sepsis	(1.5	vs	0.9	pkpy,	P	<	0.001,)	and	bone	and	joint	
infection	 (1.2	vs	0.2	pkpy,	P	<	0.001,).	Patients	with	T1DM	had	a	
higher	 rate	 of	 skin	 and	 soft	 tissue	 infection	 (11.6	 pkpy)	 than	 did	
patients	 in	 the	 T2DM	 (5.9	 pkpy)	 and	 non-	DM	 cohorts	 (2.9	 pkpy,	
P	<	0.001	Table	2).
3.3 | Unadjusted risk of progression to 
hospital admission
The	 T1DM	 cohort	 comprised	 only	 186	 patients	 and	 therefore	 its	
Kaplan-	Meier	graphs	are	difficult	to	interpret	(Figure	1A,E).
Examining	the	T2DM	cohort	by	eGFR	category,	median	time	
to	infection	could	only	be	calculated	for	the	categories	G3a,	G3b	
and	G5	 (Figure	1B);	 these	were	16.8	years	 in	G3a,	15.0	years	 in	
G3b	 and	 6.5	years	 in	 G5,	 respectively.	 Patients	with	 a	 protein-
uria	 level	 of	 A2	 had	 a	 median	 time	 to	 infection	 of	 16.7	years	
(Figure	1F).
In	the	non-	DM	cohort,	median	time	to	infection	was	15.0	years	
in	the	G4	category	and	10.9	years	in	the	G5	category	(Figure	1C).	
Examining	non-	DM	patients	by	proteinuria	 category	 (Figure	1G),	
there was a clear distinction between proteinuria levels after 
5 years.
The	Kaplan-	Meier	graphs	for	all	patients	combined	(Figure	1D,H)	
are	almost	identical	to	the	non-	DM	plots	because	87.8%	of	the	com-
bined cohort patients had no diabetes.
3.4 | Adjusted risk of progression to 
hospital admission
Adjusting	 for	 age,	 gender,	 baseline	 BMI,	 baseline	 blood	 pressure,	
HbA1c,	 smoking	 status,	 diabetes	 cohort,	 index	 year	 and	 prior	 co-
morbidities	and	examining	all	CKD	patients	together,	we	found	no	
difference	 in	 infection	 rates	 between	patients	 in	 eGFR	 categories	
G1	 and	 the	 referent	 category	G2	 (aHR	=	1.03,	 95%	CI:	 0.90-	1.17).	
However,	in	the	G3a	category	the	aHR	was	1.18	(1.13-	1.23),	in	G3b,	
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1.57	(1.49-	1.65),	in	G4,	2.28	(2.12-	2.44)	and	in	G5,	3.74	(3.16-	4.42).	
Risks	of	infection	were	higher	in	proteinuria	levels	A2	(aHR	=	1.35,	
1.26-	1.44),	A23	 (aHR	=	1.28,	 1.13-	1.44)	 and	A3	 (aHR	=	1.74,	 1.58-	
1.91)	than	in	A1.
When	compared	with	 the	non-	DM	cohort,	 those	 in	 the	T1DM	
cohort	had	the	highest	risk	of	infection	(aHR	=	2.84,	1.88-	4.30),	fol-
lowed	by	T2DM	(aHR	=	2.33,	2.11-	2.57).	There	was	no	difference	in	
infection	rates	between	gender	(Table	S3).
TABLE  1 Baseline	characteristics	for	the	type	1	diabetes	(T1DM),	type	2	diabetes	(T2DM)	and	nondiabetes	(non-	DM)	cohorts
Non- DM T2DM T1DM Overall P- value
N 85 934 11	719 186 97	839
Age,	mean	(SD),	y 69.67	(11.2) 66.98	(10.2) 47.85	(13.7) 69.3	(11.2) <0.001
Male,	n	(%) 35	006	(40.7) 6271	(53.5) 106	(57.0) 41	383	(42.3) <0.001
Duration	of	diagnosed	diabetes,	
median	(IQR),	y
— 3.23	(0.8-	8.6) 20.64	(14.1-	30.7) 3.3	(0.8-	9.0) <0.001
Duration of diagnosed renal 
disease,	median	(IQR),	y
4.25	(2.2-	6.6) 4.72	(2.7-	7.0) 2.95	(0-	5.6) 4.3	(2.2-	6.6) <0.001
BMI,	mean	(SD),	kg/m2 27.48	(5.0) 30.04	(5.9) 25.88	(3.8) 28.1	(5.4) <0.001
Systolic	BP,	mean	(SD),	mm	Hg 148.27	(21.4) 146	(20.0) 138.95	(21.7) 147.9	(21.3) <0.001
Diastolic	BP,	mean	(SD),	mm	Hg 83.16	(11.6) 80.97	(10.8) 78.25	(11.8) 82.9	(11.6) <0.001
Smoking	status,	n	(%)
Never 48	261	(56.2) 6104	(52.1) 97	(52.2) 54	462	(55.7) <0.001
Ex-	smoker 23	211	(27.0) 3561	(30.4) 38	(20.4) 26	810	(27.4)
Current 13	782	(16.0) 2016	(17.2) 50	(26.9) 15	848	(16.2)
Missing 680	(0.8) 38	(0.3) 1	(0.5) 719	(0.7)
Alcohol	status,	n	(%)
Never 16	426	(19.1) 2904	(24.8) 27	(14.5) 19	357	(19.8) <0.001
Ex-	drinker 1619	(1.9) 353	(3.0) 6	(3.2) 1978	(2.0)
Current 62	316	(72.5) 7966	(68.0) 141	(75.8) 70	423	(72.0)
Missing 5573	(6.5) 496	(4.2) 12	(6.5) 6081	(6.2)
HbA1c,	median	(IQR),	% 5.7	(5.3-	6.0) 7.5	(6.6-	9.0) 9.0	(7.9-	10.5) 7.38	(6.4-	8.8) <0.001
HbA1c,	median	(IQR),	mmol/L 38.8	(34.4-	42.0) 58.5	(48.6-	74.9) 74.9	(62.3-	90.7) 57.19	(46.5-	72.7) <0.001
Serum	creatinine,	mean	(SD),	
μmol/L
105.0	(32.1) 101.1	(30.0) 117.5	(59.2) 104.55	(32.0) <0.001
GP	contacts	in	prior	year,	median	
(IQR)
5	(3-	9) 8	(4-	14) 7	(3-	12) 5	(3-	10) <0.001
Index	date	=	1st	positive	eGFR,	n	
(%)
85	727	(99.8) 11	036	(94.2) 151	(81.2) 96	914	(99.1) <0.001
eGFR	category	at	index	date,	n	(%)
G1 — — — — <0.001
G2 42	889	(50.0) 7043	(60.1) 101	(54.3) 50	033	(51.1)
G3a 30	359	(35.4) 2725	(23.3) 19	(10.2) 33	103	(33.8)
G3b 10	034	(11.7) 972	(8.3) 15	(8.1) 11	021	(11.3)
G4 2169	(2.5) 276	(2.4) 14	(7.5) 2459	(2.5)
G5 276	(0.3) 20	(0.2) 2	(1.1) 298	(0.3)
Index	date	=	1st	positive	
proteinuria,	n	(%)
253	(0.3) 844	(7.2) 38	(20.4) 1135	(1.2) <0.001
Proteinuria	status	at	index	date,	n	(%)
A1 — — — — <0.001
A2 63	(0.1) 505	(4.3) 15	(8.0) 583	(0.6)
A23 61	(0.1) 145	(1.2) 7	(3.8) 213	(0.2)
A3 129	(0.2) 194	(1.7) 16	(8.6) 339	(0.4)
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3.5 | Adjusted risk of progression to hospital 
admission by diabetes status
Adjusted	 models	 were	 run	 for	 the	 T2DM	 and	 non-	DM	 cohorts	
(Figure	2).	The	proposed	models	were	inappropriate	in	the	T1DM	co-
hort due to low numbers.
Within	the	T2DM	cohort,	there	was	no	significant	difference	be-
tween	 G1	 (aHR	=	1.00,	 0.80-	1.25)	 and	 G3a	 (aHR	=	1.03,	 0.92-	1.15)	
compared	 with	 the	 reference	 G2.	 However,	 there	 was	 an	 associa-
tion	between	worsening	eGFR	and	 infection	rates	 in	categories	G3b	
(aHR	=	1.36,	1.20-	1.54),	G4	(aHR	=	1.82,	1.54-	2.15)	and	G5	(aHR	=	2.41,	
1.60-	3.63).	In	the	non-	DM	cohort,	there	was	no	significant	difference	
between	G1	(aHR	=	0.94,	0.80-	1.11)	and	the	reference	G2,	but	infection	
rates increased in this cohort from categories G3a to G5: the adjusted 
hazard	ratio	for	G3a	was	1.21	(1.15-	1.27),	for	G3b,	1.61	(1.52-	1.71),	for	
G4,	this	was	2.40	(2.21-	2.60)	and	for	G5,	4.15	(3.44-	5.00).
Within	the	T2DM	cohort,	aHRs	for	the	positive	proteinuria	cat-
egories	 A2,	 A23	 and	A3	were	 all	 significant	 (Figure	2).	 There	was	
an association between worsening proteinuria and infection rates 
in	 categories	 A2	 (aHR	=	1.45,	 1.29-	1.63),	 A2/3	 (aHR	=	1.31,	 1.10-	
1.57)	 and	A3	 (aHR	=	1.91,	 1.67-	2.20)	 compared	with	A1.	A	 similar	
pattern	was	seen	within	the	non-	DM	cohort	(Figure	2),	with	the	aHR	
F IGURE  1 A,	Time	to	first	hospitalized	infection	in	T1DM	cohort	by	eGFR	category.	B,	Time	to	first	hospitalized	infection	in	T2DM	
cohort	by	eGFR	category.	C,	Time	to	first	hospitalized	infection	in	non-	DM	cohort	by	eGFR	category.	D,	Time	to	first	hospitalized	
infection	in	overall	cohort	by	eGFR	category.	E,	Time	to	first	hospitalized	infection	in	T1DM	cohort	by	proteinuria	category.	F,	Time	to	first	
hospitalized	infection	in	T2DM	cohort	by	proteinuria	category.	G,	Time	to	first	hospitalized	infection	in	non-	DM	cohort	by	proteinuria	
category.	H,	Time	to	first	hospitalized	infection	in	overall	cohort	by	proteinuria	category
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TABLE  2 Rates of hospital admission with infection as the primary diagnosis
Non- DM T1DM T2DM
P- valueN
Crude event rate, 
pkpy N
Crude event rate, 
pkpy N
Crude event rate, 
pkpy
Patients 85 934 — 186 — 11	719 —
Patient	years 646	908 — 1459 — 95 935 —
Hospital	admissions
Any	listed	infection 16	101 24.9 35 24.0 3198 33.3 <0.001
Genitourinary 4707 7.3 7 4.8 1011 10.5 <0.001
Gastrointestinal 4440 6.9 3 2.1 604 6.3 <0.001
Pulmonary 4251 6.6 4 2.7 746 7.8 <0.001
Skin	and	soft	tissue 1902 2.9 17 11.6 567 5.9 <0.001
Sepsis 597 0.9 2 1.4 147 1.5 <0.001
Bone	and	joint 144 0.2 2 1.4 112 1.2 <0.001
Endocarditis 53 0.1 0 0 9 0.1 <0.001
Bacteremia 7 0.0 0 0 2 0.0 <0.001
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for	A2	 being	 1.31	 (1.20-	1.43),	 A23,	 1.25	 (1.05-	1.50)	 and	A3,	 1.61	
(1.40-	1.85).
4  | DISCUSSION
In	this	study	the	severity	of	renal	morbidity,	as	measured	by	eGFR	and	
proteinuria,	were	both	associated	with	an	 increase	 in	 infection	rates,	
and that this association was independent. McDonald et al16 published 
a	study	similar	to	ours	that	 looked	at	the	associations	between	CKD	
and	the	 incidence	of	 infection	 in	patients	with	diabetes	aged	65	and	
older.	They	 found	 that	 there	was	an	association	between	eGFR	cat-
egory and rates of lower respiratory tract infection and sepsis. Their 
results have been validated in our study of a larger population of pa-
tients	aged	40	and	older	(25	and	older	for	those	with	type	1	diabetes)	
with and without diabetes.
Much of the current rationale for intervention in patients with diabe-
tes	and	kidney	disease	is	directed	towards	use	of	ACE	inhibitors,	angio-
tensin	receptor	blockers	and	other	vascular	interventions	to	reduce	the	
risk	of	progression	both	to	end-	stage	renal	failure	and	to	cardiovascular	
events including ischaemic events and cardiac failure. The increasing 
burden of sepsis with worsening burden of renal impairment is rarely 
considered	by	clinicians.	As	potential	immunosuppressive	interventions	
for	CKD	emerge	that	may	reduce	the	fibrosis	associated	with	worsening	
diabetic	nephropathy,26 the worsening burden of infection as nephropa-
thy	progresses,	potentially	related	to	the	loss	of	immunoglobulins	via	the	
kidney	due	to	increased	glomerular	permeability,	should	be	considered	
in	the	risk-	benefit	evaluation	of	any	therapy.	Here,	hospitalized	infection	
risk	within	the	type	2	diabetes	cohort	was	seen	to	rise	as	the	severity	
of	CKD	worsened	from	G3b	to	G5	(G3a-	G5	in	overall	and	nondiabetes)	
and	proteinuria	stages	A2-	A3.	Treating	patients	at	eGFR	stages	G1-	G3a	
with immunosuppressive therapy may therefore provide a favourable 
risk-	benefit	ratio	(G1-	G3a	in	type	2	diabetes;	G1-	G2	in	nondiabetes	and	
overall	cohorts),	although	further	studies	are	required	to	explore	this.
These data and the study design had a number of strengths and 
limitations. The study included routine observations from a very large 
number	of	people,	from	a	national,	real-	world	setting.	Infection	rates	
were	compared	with	those	in	patients	with	mildly	decreased	kidney	
function	or	mild	kidney	damage,	who	might	already	be	experiencing	a	
high	number	of	hospitalized	infections.	There	was	no	standardization	
of	the	timing	of	observations	such	as	eGFR	and	proteinuria.	We	be-
lieve that this will have introduced noise but not bias because there 
is	inherent	variability	in	the	monitoring	of	kidney	function	in	routine	
care.	 In	 identifying	 the	members	of	 our	 diabetes	 cohorts,	we	may	
have selected patients having an aetiology other than diabetes for 
their	CKD.	A	limited	range	of	infections	was	included	in	the	defini-
tion,	which	may	have	led	to	bias,	and	in	addition,	the	impact	of	socio-	
economic	status	on	the	risk	of	severe	infection	was	not	factored	in.
Since	approximately	2006,	there	has	been	considerable	variability	
in	the	calibration	of	serum	creatinine	measurements	in	UK	laboratories,	
with	methodology	changes	and	the	piecemeal	introduction	of	isotope-	
dilution	mass	spectrometry	(IDMS)	reference	assays.	The	use	of	IDMS	
standards is believed to have led to a slight but systematic downward 
shift	in	serum	creatinine	values,	with	a	corresponding	upward	shift	in	
eGFR	values.	This	has	implications	for	our	study,	by	affecting	the	ap-
parent	trajectory	of	individual	patients’	eGFR	histories,	which	might	in	
turn have been incorrectly related to the infection outcome. This could 
be considered an additional limitation of the study.
Although	this	study	separately	analysed	the	effect	of	renal	impair-
ment	 and	 proteinuria	 on	 the	 risk	 of	 hospitalization	 for	 infection,	 an	
analysis of the interaction between stage of renal function and stage 
of	proteinuria	was	also	conducted.	However,	when	adjusting	for	eGFR	
category	and	proteinuria	 combinations,	 the	model	was	overparame-
trized,	and	despite	all	possible	combinations	being	tested	(eg,	A1	×	G1,	
A1	×	G2	etc.),	no	combination	showed	any	significance.	This	can	be	ex-
plained by the large proportion of missing data for proteinuria category.
In	 summary,	 it	has	already	been	established	 that	patients	with	
chronic	kidney	disease	(CKD),	particularly	ESRD,	have	an	increased	
incidence	 of	 infections,	 particularly	 those	 resulting	 in	 hospitaliza-
tions and death.13,27 There is also some evidence that patients with 
predialysis	CKD	also	have	a	higher	 risk	of	 infections	 (as	measured	
by	 infection-	related	hospitalizations)	which	correlates	to	degree	of	
renal function decline.14,16	Patients	with	diabetes	may	have	an	ad-
ditional	risk	of	infection	due	to	their	underlying	metabolic	disease.
The	current	study	demonstrates	that	eGFR	and	degree	of	albumin-
uria	are	independent	markers	of	hospitalized	infection	in	both	patients	
F IGURE  2 Adjusted	hazard	ratios	for	eGFR	(reference:	G2)	and	proteinuria	(reference:	A1)	categories	from	T2DM	and	non-DM	Cox	
models 
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G5
Proteinuria category
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A2/3
A3
HR 95% CI
1.03 (0.90-1.17)
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1.18 (1.13-1.23)
1.57 (1.49-1.65)
2.28 (2.12-2.44)
3.74 (3.16-4.42)
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1.35 (1.26-1.44)
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1.74 (1.58-1.91)
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1.36 (1.20-1.54)
1.82 (1.54-2.15)
2.41 (1.60-3.63)
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1.45 (1.29-1.63)
1.31 (1.10-1.57)
1.91 (1.67-2.20)
HR 95% CI
0.94 (0.80-1.11)
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with	and	without	diabetes,	and	validates	and	extends	previous	work	in	
a larger and more diverse population.16	The	same	patterns	of	hazard	
ratios	of	eGFR	and	proteinuria	were	seen	in	CKD	patients	with	type	
2	diabetes	and	no	diabetes,	with	the	risk	of	each	outcome	increasing	
with	a	decreasing	eGFR	and	increasing	proteinuria.	Our	findings	have	
therefore	emphasized	the	relationship	between	eGFR	and	proteinuria	
and	 their	 impact	on	 the	 risk	of	 serious	 infection.	Furthermore,	 they	
highlight	the	importance	of	monitoring	and	managing	both,	regardless	
of	diabetes	status,	and	that	both	should	be	considered	when	evaluat-
ing	the	risk-	benefit	profile	of	disease-	specific	therapies.
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